Geode Capital Management’s Pardes Biosciences, Inc. Common Stock PRDS Stock Holding History

Geode Capital Management’s Portfolio PRDS Stock Details PRDS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-228,575	Closed	-$414K	–	4835
2023 Q2	$414K	Sell	228,575 -315,782	-58%	-$577K	﹤0.01%	3717
2023 Q1	$719K	Buy	544,357 +75,541	+16%	+$124K	﹤0.01%	3503
2022 Q4	$792K	Sell	468,816 -439	-0.1%	-$556	﹤0.01%	3469
2022 Q3	$868K	Sell	469,255 -21,637	-4%	-$64.5K	﹤0.01%	3464
2022 Q2	$1.51M	Buy	490,892 +267,904	+120%	+$1.64M	﹤0.01%	3224
2022 Q1	$1.61M	Buy	+222,988	New	+$2.19M	﹤0.01%	3368

Other funds holding PRDS

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Geode Capital Management's PRDS Position: Q3 2023 in Review

Geode Capital Management sold out of Pardes Biosciences, Inc. Common Stock (PRDS) in Q3 2023, closing a stake of 228,575 shares — an estimated $414K sold.

Geode Capital Management first reported a position in PRDS in Q1 2022 and held it in 6 quarters. The position peaked at $1.61M in Q1 2022. 1 fund tracked by Wall St. Rank holds PRDS as of Q3 2023.

Geode Capital Management reported no remaining Pardes Biosciences, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Geode Capital Management sold 228,575 Pardes Biosciences, Inc. Common Stock shares in Q3 2023, an estimated $414K.
Geode Capital Management first reported a position in Pardes Biosciences, Inc. Common Stock in Q1 2022 and held it in 6 quarters.
Geode Capital Management's Pardes Biosciences, Inc. Common Stock position peaked at $1.61M in Q1 2022.
1 fund tracked by Wall St. Rank held Pardes Biosciences, Inc. Common Stock as of Q3 2023.

Based on Geode Capital Management's 13F filing for Q3 2023, filed 13 Nov 2023.